Sangamo Therapeutics, Inc.
US
Sangamo Therapeutics, Inc.: 4 links from the documents of the companies and the register.
Customers 4
| Entity | Figure | Evidence | Documents |
|---|---|---|---|
| Genentech, Inc. | 87% of the revenue of the supplier, fiscal year ended 31 Dec 2024 | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
| Eli Lilly and Company | 47% of the revenue of the supplier, fiscal year ended 31 Dec 2025 | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
| Pfizer Inc. | 28% of the revenue of the supplier, fiscal year ended 31 Dec 2025 | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
| Astellas Gene Therapies, Inc. | 19% of the revenue of the supplier, fiscal year ended 31 Dec 2025 | Stated | Form 10-K for the fiscal year ended 31 December 2025 |
Each link names the documents that state it, with the class of its evidence: stated by one party, confirmed by both, or stated by the register of legal entities. A commitment is the commitment at the date of the agreement.